Harnessing AI to improve outcomes for cancer and neurology patients, from screening to diagnosis to treatment. Find out more on our website (https://www.renovarogroup.com) and our LinkedIn page (https://www.linkedin.com/company/renovaro-biosciences-inc).https://bsky.app/profile/renovaro.bsky.socialhttps://bsky.app/profile/renovaro.bsky.social/post/3luat2a3xec2mRenovaro just published landmark preclinical data in Vaccines! Our next-gen dendritic cell therapy reduced pancreatic tumour volume by up to 81.7% in humanized mice and activated strong, targeted immune responses. 🧵 #Immunotherapy #CancerResearch #BioTech18 Jul 2025 16:02 +0000at://did:plc:b77jpon44gaj2ps3ayoom76i/app.bsky.feed.post/3luat2a3xec2mhttps://bsky.app/profile/renovaro.bsky.social/post/3lqs3z2esus2kBioSymetrics, a Renovaro company, just secured a key U.S. patent advancing AI-driven drug discovery. Our new methods unify diverse biomedical data for real-time, scalable predictive analytics – a major leap for precision medicine. #AI #DrugDiscovery #PrecisionMedicine04 Jun 2025 15:17 +0000at://did:plc:b77jpon44gaj2ps3ayoom76i/app.bsky.feed.post/3lqs3z2esus2khttps://bsky.app/profile/renovaro.bsky.social/post/3lppfqwfze22iHello Bluesky! We’re Renovaro, using AI-based precision medicine to improve outcomes in oncology and neurology. Our full-stack Bio-AI platform brings together diagnostics, drug discovery, analytics, and validation for faster, more personalized care.21 May 2025 20:08 +0000at://did:plc:b77jpon44gaj2ps3ayoom76i/app.bsky.feed.post/3lppfqwfze22i